State of Wisconsin Investment Board’s Lineage Cell Therapeutics LCTX Stock Holding History

State of Wisconsin Investment Board’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-122,600	Closed	-$135K	–	1568
2019 Q2	$135K	Buy	122,600 +2,700	+2%	+$3.11K	﹤0.01%	1513
2019 Q1	$157K	Buy	119,900 +27,500	+30%	+$34.2K	﹤0.01%	1480
2018 Q4	$84K	Buy	92,400 +27,249	+42%	+$41.7K	﹤0.01%	1505
2018 Q3	$134K	Hold	65,151	–	–	﹤0.01%	1515
2018 Q2	$117K	Hold	65,151	–	–	﹤0.01%	1453
2018 Q1	$153K	Hold	65,151	–	–	﹤0.01%	1412
2017 Q4	$123K	Hold	65,151	–	–	﹤0.01%	1414
2017 Q3	$162K	Hold	65,151	–	–	﹤0.01%	1414
2017 Q2	$180K	Buy	+65,151	New	+$182K	﹤0.01%	1408

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State of Wisconsin Investment Board's LCTX Position: Q3 2019 in Review

State of Wisconsin Investment Board sold out of Lineage Cell Therapeutics (LCTX) in Q3 2019, closing a stake of 122,600 shares — an estimated $135K sold.

State of Wisconsin Investment Board first reported a position in LCTX in Q2 2017 and held it in 9 quarters. The position peaked at $180K in Q2 2017. 96 funds tracked by Wall St. Rank hold LCTX as of Q3 2019.

State of Wisconsin Investment Board reported no remaining Lineage Cell Therapeutics position as of Q3 2019 after selling out during the quarter.
State of Wisconsin Investment Board sold 122,600 Lineage Cell Therapeutics shares in Q3 2019, an estimated $135K.
State of Wisconsin Investment Board first reported a position in Lineage Cell Therapeutics in Q2 2017 and held it in 9 quarters.
State of Wisconsin Investment Board's Lineage Cell Therapeutics position peaked at $180K in Q2 2017.
96 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2019.

Based on State of Wisconsin Investment Board's 13F filing for Q3 2019, filed 12 Nov 2019.